Withholding and withdrawing treatment for cost-effectiveness reasons: Are they ethically on par?


Journal

Bioethics
ISSN: 1467-8519
Titre abrégé: Bioethics
Pays: England
ID NLM: 8704792

Informations de publication

Date de publication:
02 2019
Historique:
received: 23 05 2018
revised: 10 10 2018
accepted: 16 10 2018
pubmed: 12 12 2018
medline: 27 11 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

In healthcare priority settings, early access to treatment before reimbursement decisions gives rise to problems of whether negative decisions for cost-effectiveness reasons should result in withdrawing treatment, already accessed by patients. Among professionals there seems to be a strong attitude to distinguish between withdrawing and withholding treatment, viewing the former as ethically worse. In this article the distinction between withdrawing and withholding treatment for reasons of cost effectiveness is explored by analysing the doing/allowing distinction, different theories of justice, consequentialist and virtue perspectives. The authors do not find any strong reasons for an intrinsic difference, but do find some reasons for a consequentialist difference, given present attitudes. However, overall, such a difference does not, all things considered, provide a convincing reason against withdrawal, given the greater consequentialist gain of using cost-effective treatment. As a result, patients should be properly informed when given early access to treatment, that such treatment can be later withdrawn following a negative reimbursement decision.

Identifiants

pubmed: 30536795
doi: 10.1111/bioe.12545
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-286

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Lars Sandman (L)

Linkopings universitet, Linkoping, Sweden.

Jan Liliemark (J)

Linkopings universitet, Linkoping, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH